Predictors of blood pressure response to intensified and fixed combination treatment of hypertension: The ACCOMPLISH study

Blood Pressure

Volumn 17, Issue 1, 2008, Pages 7-17

  Kjeldsen, Sverre E ^a,b   Jamerson, Kenneth A ^a   Bakris, George L ^c   Pitt, Bertram ^a   Dahlöf, Bjorn ^d   Velazquez, Eric J ^e   Gupte, Jitendra ^f   Staikos, Linda ^f   Hua, Tsushung A ^f   Shi, Victor ^f   Hester, Allen ^f   Tuomilehto, Jaakko ^g   Östergren, Jan ^h   Ibsen, Hans ^h   Weber, Michael ⁱ  

^a UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^b UNIVERSITY OF OSLO   (Norway)

^c UNIVERSITY OF CHICAGO   (United States)

^d SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^e DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f NOVARTIS PHARMA AG   (Switzerland)

^g HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^h KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

ⁱ Downstate Health Sciences University   (United States)

Author keywords

Clinical trial; Combination therapy; Hypertension; Predictor variables

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; AMLODIPINE BESYLATE PLUS BENAZEPRIL; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; BENAZEPRIL PLUS HYDROCHLOROTHIAZIDE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CLONIDINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; INSULIN; INSULIN SENSITIZING AGENT; LOOP DIURETIC AGENT; ORAL ANTIDIABETIC AGENT; THIAZIDE DIURETIC AGENT;

ADD ON THERAPY; ADULT; AGED; ARTICLE; BLOOD PRESSURE MONITORING; BLOOD PRESSURE REGULATION; CAUCASIAN; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETES MELLITUS; DIABETIC PATIENT; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG DOSE TITRATION; DRUG RESPONSE; FEMALE; FOLLOW UP; GEOGRAPHIC DISTRIBUTION; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; ORGAN INJURY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROTEINURIA; RACE DIFFERENCE; RANDOMIZED CONTROLLED TRIAL; SYSTOLIC BLOOD PRESSURE; SYSTOLIC HYPERTENSION; TARGET ORGAN; UNITED STATES; UNIVARIATE ANALYSIS;

AGED; AMLODIPINE; ANTIHYPERTENSIVE AGENTS; BENZAZEPINES; BLOOD PRESSURE; CONTINENTAL POPULATION GROUPS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG RESISTANCE; DRUG THERAPY, COMBINATION; FEMALE; FINLAND; HUMANS; HYDROCHLOROTHIAZIDE; HYPERTENSION; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PREDICTIVE VALUE OF TESTS; RISK ASSESSMENT; SCANDINAVIA; TREATMENT OUTCOME; UNITED STATES;

EID: 45949110400     PISSN: 08037051     EISSN: 16511999     Source Type: Journal    
DOI: 10.1080/08037050801972857     Document Type: Article

References (29)

1. Chobanian, A. V., Bakris, G. L., Black, H. R., Cushman, W. C., Green, L. A., Izzo, J. L Jr. and the National High Blood Pressure Education Program Coordinating Committee et al. (2003) The seventh report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure. The JNC7 Report. JAMA, 289, pp. 2560-2572.
2. McMurray, M. (1999) The health economics of the treatment of hyperlipidemia and hypertension. Am J Hypertens, 12, pp. 99S-104S.
3. Hansson, L., Zanchetti, A., Carruthers, S. G., Dahlof, B., Elmfeldt, D., Julius, S. for the HOT Study Group et al. (1998) Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: Principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet, 351, pp. 1755-1762.
4. UK Prospective Diabetes Study Group (1998) Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ, 317, pp. 703-713.
5. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group (2002) Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs. diuretic: The Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA, 288, pp. 2981-2997.
6. Black, H. R. (1999) Optimal blood pressure: How low should we go?. Am J Hypertens, 12, pp. 113S-120S.
7. Jamerson, K., Bakris, G. L., Dahlof, B., Pitt, B., Velazquez, E. Gupte, J. et al. (2007) Exceptional early blood pressure control rates: The ACCOMPLISH Trial. Blood Press, 16, pp. 80-86.
8. Jamerson, K. A., Bakris, G. L., Wun, C. C., Dahlof, B., Lefkowitz, M. Manfreda, S. et al. (2004) Rationale and design of the Avoiding Cardiovascular events through COMbination therapy in Patients LIving with Systolic Hypertension (ACCOMPLISH) Trial. Am J Hypertens, 17, pp. 793-801.
9. Weber, M. A., Bakris, G. L., Dahlof, B., Pitt, B., Velazquez, E. Gupte, J. et al. (2007) Baseline characteristics in the Avoiding Cardiovascular events through COMbination therapy in Patients LIving with Systolic Hypertension (ACCOMPLISH) trial: A hypertensive population at high cardiovascular risk. Blood Press, 16, pp. 13-19.
10. Jamerson, K. A., Nwose, O., Jean-Louis, L., Schofield, L., Purkayastha, D. and Baron, M. (2004) Initial angiotensin-converting enzyme inhibitor/ calcium channel blocker combination therapy achieves superior blood pressure control compared with calcium channel blocker monotherapy in patients with stage 2 hypertension. Am J Hypertens, 17, pp. 495-501.
11. Weber, M. A. (2003) The ALLHAT Report: A case of information and misinformation. J Clin Hypertens, 5, pp. 9-13.
12. Julius, S., Kjeldsen, S. E., Weber, M., Brunner, H. R., Ekman, S., Hansson, L. for the VALUE trial group et al. (2004) Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: The VALUE randomized trial. Lancet, 363, pp. 2022-2031.
13. (2003) 2003 European Society of Hypertension-European Society of Cardiology guidelines for the Management of Arterial Hypertension. J Hypertens, 21, pp. 1011-1054.
14. Burt, V. L., Whelton, P., Roccella, E. J., Brown, C., Cutler, J. A. Higgins, M. et al. (1995) Prevalence of hypertension in the US adult population; results from the Third National Health and Nutrition Examination Survey. Hypertension, 25, pp. 305-313.
15. Neutel, J. M., Smith, D. H. G. and Weber, M. A. (2004) Effect of antihypertensive monotherapy and combination therapy on arterial distensibility and left ventricular mass. Am J Hypertens, 17, pp. 37-42.
16. White, W. B., Giles, T., Bakris, G. L., Neutel, J. M., Davidai, G. and Weber, M. A. (2006) Measuring the efficacy of antihypertensive therapy by ambulatory blood pressure monitoring in the primary care setting. Am Heart J, 151, pp. 176-184.
17. Dahlof, B., Sever, P. S., Poulter, N. R., Wedel, H., Beevers, D. G., Caulfield, M. for the ASCOT Investigators et al. (2005) Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): A multicentre randomized controlled trial. Lancet, 366, pp. 895-906.
18. Poulter, N. R., Wedel, H., Dahlof, B., Sever, P. S., Beevers, D. G. Caulfield, M. et al. (2005) Role of blood pressure and other variables in the differential cardiovascular event rates noted in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA). Lancet, 366, pp. 907-913.
19. Hansson, L., Lindholm, L. H., Niskanen, L., Lanke, J., Hedner, T., Niklason, A. for the Captopril Prevention Project (CAPPP) study group et al. (1999) Effect of angiotensin-converting enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: The Captopril Prevention Project (CAPPP) randomized trial. Lancet, 353, pp. 611-616.
20. Hansson, L., Lindholm, L. H., Ekbom, T., Dahlof, B., Lanke, J., Schersten, B. for the STOP-Hypertension-2 study group et al. (1999) Randomized trial of old and new antihypertensive drugs in elderly patients: Cardiovascular mortality and morbidity, the Swedish Trial in Old Patients with Hypertension-2 study. Lancet, 354, pp. 1751-1756.
21. Hansson, L., Hedner, T., Lund-Johansen, P., Kjeldsen, S. E., Lindholm, L. H., Syvertsen, J. O. for the NORDIL Study Group et al. (2000) Randomized trial effects of calcium antagonists compared with diuretics and β-blockers on cardiovascular morbidity and mortality in hypertension: The Nordic Diltiazem (NORDIL) study. Lancet, 356, pp. 359-365.
22. Brown, M. J., Palmer, C. R., Castaigne, A., de Leeuw, P. W., Mancia, G. Rosenthal, T. et al. (2000) Morbidity and mortality in patients randomized to double-blind treatment with a long-acting calcium-channel blocker or diuretic in the International Nifedipine GITS study: Intervention as a Goal in Hypertension Treatment (INSIGHT). Lancet, 356, pp. 365-372.
23. Dahlof, B., Devereux, R. B., Kjeldsen, S. E., Julius, S., Beevers, G., de Faire, U. for the LIFE study group et al. (2002) Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): A randomized trial against atenolol. Lancet, 359, pp. 995-1003.
24. Cushman, W. C., Ford, C. E., Cutler, J. A., Margolis, K. L., Davis, B. R., Grimm, R. H. for the ALLHAT Research Group et al. (2002) Success and predictors of blood pressure control in diverse North American settings: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). J Clin Hypertens, 4, pp. 393-404.
25. Weber, M. A., Julius, S., Kjeldsen, S. E., Brunner, H. R., Ekman, S. Hansson, L. et al. (2004) Blood pressure dependent and independent effects of antihypertensive treatment on clinical events in the VALUE trial. Lancet, 363, pp. 2049-2051.
26. Sever, P. S., Dahlof, B., Poulter, N. R., Wedel, H., Beevers, G., Caulfield, M. for the ASCOT Investigators et al. (2003) Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Angio-Scandinavian Cardiac Outcomes Trial-Lipid lowering Arm (ASCOT-LLA): A multicentre randomized controlled trial. Lancet, 361, pp. 1149-1158.
27. Kjeldsen, S. E., Dahlof, B., Devereux, R. B., Julius, S., de Faire, U., Fyhrquist, F. for the LIFE Study Group et al. (2000) Lowering of blood pressure and predictors of response in patients with left ventricular hypertrophy. Am J Hypertens, 13, pp. 899-906.
28. Julius, S., Kjeldsen, S. E., Brunner, H., Hansson, L., Platt, F., Ekman, S. for the Value Trial et al. (2003) VALUE Trial: Long-term blood pressure trends in 13,449 patients with hypertension and high cardiovascular risk. Am J Hypertens, 16, pp. 544-548.
29. Campo, C., Segura, J. and Ruilope, L. M. (2002) Factors influencing the systolic blood pressure response to drug therapy. J Clin Hypertens, 4, pp. 35-40.